What Is the Placebo Effect in Clinical Trials

By Kevin Fernando · Oct 5, 2026 · 7 min read

The placebo effect in clinical trials is the measurable improvement patients experience from receiving an inert treatment. It's not a flaw in trial design but a benchmark: a drug's true benefit is only the improvement it achieves beyond what placebo alone produces. Placebo response can account for as much as 60% of measured treatment response, making it critical to isolate.

When a patient receives a treatment they believe will help them, they often improve even if the treatment contains no active ingredient. That improvement is the placebo effect, and it appears in every clinical trial. Understanding what it is, how researchers measure it, and why it matters is essential to reading trial results honestly. The placebo effect is not a sign that a drug failed; it is the benchmark against which a drug's true benefit is measured.

What the placebo effect is in clinical trials

The placebo effect in clinical trials is the measurable health improvement patients report or demonstrate after receiving an inert treatment, a substance with no pharmacological activity. A patient taking a sugar pill might report reduced pain, improved mood, or better sleep. A patient receiving a saline injection might show lower blood pressure or reduced inflammation on a clinical measure. These improvements are real and measurable, even though the treatment itself is inactive. The placebo effect is not imaginary or fraudulent; it is a genuine physiological and psychological response that occurs when patients expect to improve. Understanding this response is the foundation for interpreting whether a drug's benefits come from the drug itself or from the context and expectations surrounding its use.

How placebo response is measured

Researchers quantify the placebo effect so they can compare it to the drug's effect and determine whether the drug provides a real benefit. The measurement approach is straightforward but critical to understanding trial results.

Baseline versus post-treatment improvement

Placebo response is measured as the degree of improvement from baseline to endpoint in the placebo arm. Baseline is the patient's condition at the start of the trial, before any treatment. Endpoint is the patient's condition at the end of the trial. The placebo response is the gap between these two points. If a patient reports a pain score of 8 out of 10 at baseline and a pain score of 4 out of 10 at endpoint after receiving placebo, the placebo response is a 4-point improvement. This measurement isolates what improvement occurs in the absence of an active drug, allowing researchers to see how much additional benefit the actual drug provides.

Worked example with invented numbers

Suppose a trial enrolls 100 patients with moderate depression. At baseline, the average depression score is 20 on a standard scale. After 12 weeks, patients in the placebo arm show an average score of 14, a 6-point improvement. Patients in the drug arm show an average score of 10, a 10-point improvement. The placebo response is 6 points. The drug's additional benefit beyond placebo is 4 points (10 minus 6). This 4-point difference is what proves the drug works better than placebo alone. If the drug arm had improved only to a score of 15, the drug would have added just 1 point of benefit beyond placebo, a much weaker result. The placebo response is not subtracted from the trial or treated as a failure; it is the baseline from which the drug's true effect is measured.

Why placebo response matters to drug efficacy

Efficacy is defined as the maximum ability of a drug or treatment to produce a result regardless of dosage. Efficacy is measured under ideal conditions with expert supervision in a group of patients through a controlled clinical trial. The placebo effect is the essential control in that measurement. Without it, a researcher cannot distinguish between improvement caused by the drug and improvement caused by expectation, natural disease progression, or the act of being in a trial. A Phase 3 trial evaluates the drug's therapeutic effect in larger, more heterogeneous populations and compares the drug with existing treatments, a placebo, or both. The placebo arm is not a waste of resources or an ethical compromise; it is the only way to know whether the drug's benefit is real. If a drug improves symptoms by 10 points and placebo improves symptoms by 9 points, the drug's true benefit is 1 point. That 1-point difference is what efficacy rests on. Placebo response can account for as much as 60% of the measured treatment response across indications with pharmacologic interventions, which means ignoring placebo would vastly overstate what the drug actually does.

Factors that influence placebo response strength

Placebo response is not a fixed quantity. It varies across trials, diseases, and patient populations because it is driven and moderated by multiple bio-psycho-social factors including participant genetics, number of study sites, baseline severity, expectations, number of treatment arms and conditioning, and behaviors of site personnel. Individual determinants such as age, clinical determinants such as baseline symptom severity, and psychological determinants such as expectations all influence placebo and nocebo outcomes. Contextual determinants, including trial design and the method of treatment administration, also play critical roles. A patient's belief that they will get better can actually drive symptom improvement. This means that a trial conducted at a single site with experienced staff and high patient expectations will produce a different placebo response than a trial conducted across many sites with variable patient populations and less structured communication. The strength of placebo response also depends on the condition being studied. Some conditions are more responsive to expectation and contextual factors than others. Understanding these drivers helps researchers interpret why placebo response differs across trials and why the same drug might show different efficacy results in different trial designs.

The placebo effect in the placebo arm versus the drug arm

A common misunderstanding is that only the placebo arm experiences placebo response. In reality, both arms do. Patients in the drug arm also have expectations, receive attention from staff, and benefit from the context of being in a trial. On average, 54% of the overall treatment effect was attributable to contextual effects. The drug arm's total improvement includes both the drug's pharmacological effect and the placebo response layered on top of it. The placebo arm's improvement is placebo response alone. The drug's true benefit is the difference between these two. If the drug arm improves by 10 points and the placebo arm improves by 6 points, the drug contributes 4 points of benefit. The 6 points of improvement in the placebo arm is not wasted information; it is the essential reference point that makes the 4-point drug benefit meaningful.

Common misreadings of placebo effect data

Readers interpreting trial results often misunderstand what placebo response means and what it reveals about a drug's efficacy. Two errors are most common and most consequential to getting the conclusion right.

Confusing placebo response with trial failure

A large placebo response does not mean the drug failed. It means the drug's benefit must exceed a high baseline to prove efficacy. Suppose a trial shows a placebo response of 8 points and a drug response of 11 points. Some readers interpret the large placebo response as a sign that the trial was poorly designed or that the drug is weak. In fact, the drug still beat placebo by 3 points, which is a real benefit. The trial was well-designed because it measured that benefit accurately. A trial with a small placebo response, say 2 points, would show the drug's benefit more dramatically if the drug improved patients by 5 points. But a trial with a large placebo response is not a failure; it is simply a trial where context and expectation play a large role in symptom improvement. The drug's ability to exceed that contextual baseline is what matters.

Assuming placebo effect is identical across all conditions

Placebo response varies dramatically across diseases and conditions, so one trial's placebo effect does not predict another's. In cancer randomized controlled trials from 2015 to 2021, the overall placebo response rate was 1%, almost entirely partial responses. In borderline personality disorder monotherapy trials, the placebo response rate was 39.2%. These are not different trials of the same drug; they are trials in fundamentally different conditions where expectation and contextual factors play different roles. A reader who sees a 30% placebo response in a psychiatric trial and then encounters a 5% placebo response in a pain trial should not conclude that the second trial is better designed or that the drug is more effective. The conditions themselves drive different baseline placebo responses. In trials with lower baseline placebo response in borderline personality disorder, the placebo response rate was 26.6%, showing that even within a single condition, trial design and patient selection influence placebo response. Interpreting a drug's benefit requires understanding what placebo response is typical for that condition, not comparing it to trials in other disease areas.

How placebo effect connects to trial design choices

Understanding placebo response explains why researchers use specific trial structures to isolate a drug's true benefit. Double-blind trials are seen as the most reliable type of study because they involve neither the participant nor the doctor knowing who has received what treatment. In a double-blind trial, neither the patient nor the caregivers are aware of the treatment assignment. This design minimizes the influence of expectations and behaviors that would amplify placebo response. The term blinding in controlled trials usually refers to keeping study participants, those involved with their management, and those collecting and analysing clinical data unaware of the assigned treatment, so that they should not be influenced by that knowledge. By blinding all parties, researchers reduce the contextual factors that drive placebo response, making it easier to measure the drug's pharmacological effect. The number of trial arms also influences placebo response; more trial arms are associated with higher placebo responder rates. Researchers designing trials must account for these factors when planning their studies and interpreting results. The placebo effect is not a problem to eliminate; it is a phenomenon to measure, understand, and control so that a drug's true benefit can be seen clearly.

Do this automatically

Calculating placebo response across multiple trial arms, measuring baseline scores, tracking post-treatment improvements, and comparing the magnitude of change between placebo and active treatment groups, requires manual data collection, statistical analysis, and repeated verification across dozens or hundreds of patients over weeks or months. This measurement workflow can be systematized and accelerated through software that automates the capture, calculation, and comparison of these baseline-to-endpoint improvements. Healthcare research reads ClinicalTrials.gov records, regulatory filings, and published literature directly, and cites each claim to the record it came from, across as many subjects as you need, with Mimir attaching a citation to every figure. It will not predict a trial's outcome or advise on anyone's treatment. Those decisions stay with clinicians and regulators, and deliberately so. Every plan includes it, including the free one.

Start your first report and run it on something you already know well.

This article is general information about healthcare and life-sciences topics. It is not medical advice, diagnosis, or treatment guidance, and it is not a substitute for a qualified professional. Any treatment decision should be discussed with a clinician.